ACCOUNT

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

CLASSIFIEDS

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Alterity Therapeutics Limited - American Depositary Shares (NQ:ATHE)

5.460 -0.120 (-2.15%)

Streaming Delayed Price Updated: 9:32 AM EDT, Jul 9, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	5,021
Open	5.180
Bid (Size)	5.350 (100)
Ask (Size)	5.670 (100)
Prev. Close	5.580
Today's Range	5.180 - 5.460
52wk Range	2.660 - 7.000
Shares Outstanding	2,084,016,678
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy

July 07, 2026

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy

June 09, 2026

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Performance

YTD	+72.8%	+72.8%
1 Month	+39.3%	+39.3%
3 Month	+40.0%	+40.0%
6 Month	+70.1%	+70.1%
1 Year	+32.8%	+32.8%

More News

Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy

May 19, 2026

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy

May 11, 2026

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026

May 07, 2026

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update

April 30, 2026

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy

April 27, 2026

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology

April 22, 2026

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors

April 17, 2026

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting

April 16, 2026

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy

April 15, 2026

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program

March 30, 2026

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit

March 09, 2026

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor

March 04, 2026

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

March 02, 2026

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

January 30, 2026

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026

January 21, 2026

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

November 12, 2025

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System

November 10, 2025

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

October 31, 2025

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 14, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 09, 2025

Via Benzinga

Thursday's after hours session: top gainers and losers ↗

October 09, 2025

Via Chartmill

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

October 09, 2025

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

October 02, 2025

From ALTERITY THERAPEUTICS LIMITED

Via GlobeNewswire

Frequently Asked Questions

Is Alterity Therapeutics Limited - American Depositary Shares publicly traded?

Yes, Alterity Therapeutics Limited - American Depositary Shares is publicly traded.

What exchange does Alterity Therapeutics Limited - American Depositary Shares trade on?

Alterity Therapeutics Limited - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Alterity Therapeutics Limited - American Depositary Shares?

The ticker symbol for Alterity Therapeutics Limited - American Depositary Shares is ATHE on the Nasdaq Stock Market

What is the current price of Alterity Therapeutics Limited - American Depositary Shares?

The current price of Alterity Therapeutics Limited - American Depositary Shares is 5.460

When was Alterity Therapeutics Limited - American Depositary Shares last traded?

The last trade of Alterity Therapeutics Limited - American Depositary Shares was at 07/09/26 09:32 AM ET

What is the market capitalization of Alterity Therapeutics Limited - American Depositary Shares?

The market capitalization of Alterity Therapeutics Limited - American Depositary Shares is 11.38B

How many shares of Alterity Therapeutics Limited - American Depositary Shares are outstanding?

Alterity Therapeutics Limited - American Depositary Shares has 11B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.